https://scholars.lib.ntu.edu.tw/handle/123456789/641519
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Jian, Cheng-Zhe | en_US |
dc.contributor.author | Lin, Li | en_US |
dc.contributor.author | Hsu, Chia-Lang | en_US |
dc.contributor.author | Chen, Yu-Hsin | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Tan, Ching-Ting | en_US |
dc.contributor.author | Ou, Da-Liang | en_US |
dc.date.accessioned | 2024-03-28T02:29:53Z | - |
dc.date.available | 2024-03-28T02:29:53Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 13596446 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/641519 | - |
dc.description.abstract | CD40, a novel immunomodulatory cancer therapy target, is expressed by B cells, macrophages, and dendritic cells (DCs) and mediates cytotoxic T cell priming through the CD40 ligand. Some tumors show promising responses to monotherapy or combination therapy with agonistic anti-CD40 antibodies. The development of improved anti-CD40 antibodies makes CD40 activation an innovative strategy in cancer immunotherapy. In this review, we trace the history of CD40 research and summarize preclinical and clinical findings. We emphasize the ongoing development of improved anti-CD40 antibodies and explore strategies for effective combination therapies. Guided by predictive biomarkers, future research should identify patient populations benefiting the most from CD40 activation. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Drug discovery today | en_US |
dc.subject | CD40; CD40 ligand; immune checkpoint inhibitor; immunomodulatory; immunotherapy | en_US |
dc.title | A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies | en_US |
dc.type | journal article | en_US |
dc.type | review | en_US |
dc.identifier.doi | 10.1016/j.drudis.2024.103893 | - |
dc.identifier.pmid | 38272173 | - |
dc.identifier.scopus | 2-s2.0-85183921468 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85183921468 | - |
dc.relation.journalvolume | 29 | en_US |
dc.relation.journalissue | 3 | en_US |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。